Neurocrine Biosciences Presents New Analysis Establishing Benchmark for Clinically Meaningful Change in Overall Health Reported by Patients with Tardive Dyskinesia
Neurocrine Biosciences presented a new analysis establishing a 6-point increase on the EQ Visual Analogue Scale as the threshold for clinically meaningful change in overall health for tardive dyskinesia patients. The findings contextualize Phase 4 KINECT-PRO results, where INGREZZA-treated patients reported a mean 13.1-point improvement in EQ-VAS scores at Week 24 — more than double the newly defined benchmark.
Key figures
- Drug Name
- INGREZZA (valbenazine)
- Phase Of Trial
- Phase 4
- Td population us adults
- 800000
- Eq vas mean improvement points
- 13.1
- Eq vas meaningful change threshold points
- 6
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.